CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.35
+7.80%Year over year
Reported trailing growth
- Revenue
- -87.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- -6.2%
- Operating cash flow
- -6.4%
Forward estimates
Based on analyst estimates
- Revenue
- +1.7%
- EBITDA
- -31.8%
- EPS
- -5.2%
Three-year CAGR
- Revenue
- +12.8%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +12.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026